Global
CN
EN
About
Development milestones
Mission&Vision
Founder
Research Achievement
Technology Platforms
Single domain antibody
Five core technology platforms
PIPELINE
BUSINESS PARTNERSHIPS
Product Out-Licensing
Co-Development
investor
Career development
Our Story
Social Recruitment
News
Company News
Media
Contact Us
Company Address
Online Message
×
Home
中文
EN
About
About Novamab
Technology Platforms
PIPELINE
BUSINESS PARTNERSHIPS
Market target layout
Strategic Cooperation
Career development
News
Company News
Media
Contact Us
Our Story
Share the latest information
Our Story
News
Company News
Media
2025-05-13
Novamab to Present Phase IIa Clinical Trial Data of LQ036 at ATS 2025
More
2023-05-12
Novamab will present the latest progress of its promising products at ATS 2023 and BIO International Convention 2023
More
2023-04-06
Novamab:Systematic Opportunities for Antibody Inhalation Administration
More
2023-01-06
The clinical trial of Novamab's inhaled TSLP nanoantibody drug LQ043H was approved by CDE
More
2022-11-30
LQ036, the world's first inhaled sdAb drug for the treatment of moderate and severe asthma, has completed the administration of the first patient in China's clinical phase I!
More
2022-11-29
The research results of Novamab long-acting IL-5 nanoantibody were published in Research Research!
More
2022-11-11
Exclusive interview with Dr. Wan Yakun: the fifth anniversary of Novamab, the next goal is Ablynx
More
2022-11-02
Wan Yakun of Novamab: Dream of Zhangjiang Science City, and brave the difficulties of nanoantibody pharmaceutical
More
2022-10-17
Novamab | Five years of joint efforts to start a new journey
More
2022-09-27
Novamab won the support of Shanghai's 2022 annual innovation fund plan
More
2022-09-16
Novamab was listed in "Top 100 Chinese pharmaceutical innovative seed enterprises in 2022"
More
总计 53
1
2
3
4
5
6